[Neonatal risks of drugs exposure at the end of pregnancy].
Foetal drugs exposure consequences depend according to the drug involved and to the length of the exposure which in the sum of length of treatment and of drug elimination (5 half life). Decisions are based upon risk evaluation and are a compromise between a risk banalisation and an excess of carefully. We described risks management for drugs used for a disease due to the pregnancy (glucocorticoïdes, antibiotics) then for drugs used for a chronic disease often preceding the pregnancy (non steroidal anti-inflammatory, serotonin recapture inhibitors, benzodiazepines, antiepileptics, conversion enzyme inhibitors/renine angiotensine antagonists, betabloquants). We also present the elements to take in account for the best drug choice at the end of pregnancy and/or for an adapted advice if the drug has been already taken: the drug itself (pharmacological effects, kinetics in neonate, toxicity marker, risk detection tool), drug amount possibly received by the neonate and literature data about neonatal manifestations due to the drug.
Centre Régional de Pharmacovigilance et d'Information sur le Médicament, Tours, France. autret-leca@med.univ-tours.fr
Elisabeth
E
Autret-Leca
Hawaré
H
Cissoko
Annie Pierre
AP
Jonville-Béra
D000328:Adult; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D004364:Pharmaceutical Preparations / Q000378:metabolism; D010599:Pharmacokinetics; D011247:Pregnancy; D011263:Pregnancy Trimester, Third / Q000502:physiology*; D018570:Risk Assessment; D012308:Risk Management
D004364:Pharmaceutical Preparations